Do the results and approval based on ADAURA trial suggest a role for adjuvant osimertinib in patients with stage IIIB-C, EGFR mutant patients treated with concurrent chemoradiation?  

ADAURA trial was not designed to address this issue. But that being said, we need to remember few things before considering "maintenance durvalumab" in patients with EGFR-mutant lung cancer, following chemo-radiation: 1. EGFR-mutant NSCLC patients may not derive any clinical bene...

The ADAURA trial did not address this issue and similarly, the Pacific trial did not address whether patients with driver alterations should receive durvalumab after CT/RT. It is certainly highly likely that adjuvant osimertinib would increase DFS but uncertain whether it would improve overall survi...